• Pitt
  • Health Sciences
  • UPMC
Regenerative Medicine at the McGowan InstituteRegenerative Medicine at the McGowan InstituteRegenerative Medicine at the McGowan InstituteRegenerative Medicine at the McGowan Institute
  • Home
  • Our People
    • Faculty/Staff Bios
    • Core Faculty Publications
    • Administrative Resources
  • Our Innovations
    • Impact
    • Patent Matrix
    • Featured Innovations
      • Innovation Insights
      • Coulter Programs
      • Expert Exposés
      • Spinout Spotlight
    • Partnerships & Collaborations
      • Industry
      • Academia
      • Within Pitt
    • Contact
  • About Us
    • Welcome
    • Video
    • Statistics
    • Mission Statement
    • What Is Regenerative Medicine?
    • Contact Us
    • Clinical Site
  • Our Research
    • Focus Areas
      • Tissue Engineering and Biomaterials
      • Cellular Therapies
      • Medical Devices and Artificial Organs
      • Clinical Translation
    • Matrix
    • Centers
    • Laboratories
    • Clinical Trials
    • Initiatives
  • Media
    • Current News
    • News Archive
    • Video
    • Podcasts
    • Newsletter
    • Grant of the Month
    • Publication of the Month
    • Media Contact
    • Video Links
  • Professional Development
    • Seminar Series
    • Special Events
    • Student Interest Groups
    • CATER
    • Post-Doctoral Opportunities
    • Career Opportunities
    • Wiegand Summer Internship
    • Admissions
    • Summer School
    • 2020 Scientific Retreat
    • Human Performance Optimization Symposium

CoreValve U.S. Pivotal High-Risk Trial: 5-Year Durability Data

    Cellular Therapy CoreValve U.S. Pivotal High-Risk Trial: 5-Year Durability Data

    CoreValve U.S. Pivotal High-Risk Trial: 5-Year Durability Data

    By: The McGowan Institute For Regenerative Medicine | Category: Cellular Therapy, News Archive | October 4, 2018

    GleasonT

    Medtronic, a global leader in heart valve therapies, recently announced new data presented at the 30th Transcatheter Cardiovascular Therapeutics (TCT) conference, the annual scientific symposium of the Cardiovascular Research Foundation. During the meeting, investigators—including McGowan Institute for Regenerative Medicine affiliated faculty member Thomas Gleason, MD, the Ronald V. Pellegrini Endowed Professor of Cardiothoracic Surgery and Chief, Division of Cardiac Surgery of the University of Pittsburgh School of Medicine, Co-Director of the Heart and Vascular Institute at UPMC, Director of the Center for Thoracic Aortic Disease, Co-Director of the Center for Heart Valve Disease, and member of the Center for Vascular Remodeling and Regeneration at Pitt—presented the longest-term data to-date from the CoreValve U.S. Pivotal Trial

    The longest-term follow-up data ever presented from the randomized trial showed that patients implanted with Medtronic’s CoreValve(TM) System experienced excellent valve durability out to five years with low severe hemodynamic structural valve deterioration (0.8 percent) compared to patients who received a surgical aortic valve replacement (SAVR) (1.8 percent). Of the 750 patients (391 transcatheter aortic valve replacement (TAVR); 359 SAVR) followed out to five years, patients treated with the CoreValve System showed similar outcomes compared to surgery for the primary endpoint of all-cause mortality 55.3 percent versus 55.4 percent; p=0.50). Additionally, rates were similar for major stroke (12.3 percent versus 13.2 percent; p=0.49) at five years.

    “These were early CoreValve patients, some of the first patients to receive the therapy, and it’s reassuring to see that the CoreValve System has proven to be durable out to five years,” said Dr. Gleason, who presented the data at the meeting. “As the technology and heart team experience continues to improve, this longer-term follow-up data is an encouraging indicator for TAVR patients in the future. Earlier concerns regarding the durability of TAVR are certainly tempered by these mid-term data.”

    Read more…

    Medtronic News Release

    Post Bulletin

    Print Friendly
    No tags.

    • site map
    • links
    • contact
    • subscribe to our newsletter
    © Copyright 2019 McGowan Institute for Regenerative Medicine
    A program of the University of Pittsburgh and the University of Pittsburgh Medical Center
    • Home
    • Our People
      • Faculty/Staff Bios
      • Core Faculty Publications
      • Administrative Resources
    • Our Innovations
      • Impact
      • Patent Matrix
      • Featured Innovations
        • Innovation Insights
        • Coulter Programs
        • Expert Exposés
        • Spinout Spotlight
      • Partnerships & Collaborations
        • Industry
        • Academia
        • Within Pitt
      • Contact
    • About Us
      • Welcome
      • Video
      • Statistics
      • Mission Statement
      • What Is Regenerative Medicine?
      • Contact Us
      • Clinical Site
    • Our Research
      • Focus Areas
        • Tissue Engineering and Biomaterials
        • Cellular Therapies
        • Medical Devices and Artificial Organs
        • Clinical Translation
      • Matrix
      • Centers
      • Laboratories
      • Clinical Trials
      • Initiatives
    • Media
      • Current News
      • News Archive
      • Video
      • Podcasts
      • Newsletter
      • Grant of the Month
      • Publication of the Month
      • Media Contact
      • Video Links
    • Professional Development
      • Seminar Series
      • Special Events
      • Student Interest Groups
      • CATER
      • Post-Doctoral Opportunities
      • Career Opportunities
      • Wiegand Summer Internship
      • Admissions
      • Summer School
      • 2020 Scientific Retreat
      • Human Performance Optimization Symposium
    Regenerative Medicine at the McGowan Institute